Cost Analysis: Port Delivery System versus Monthly Ranibizumab for Wet Age-Related Macular Degeneration Treatment

Ophthalmol Retina. 2022 Nov;6(11):1105-1106. doi: 10.1016/j.oret.2022.05.021. Epub 2022 May 27.
No abstract available

Keywords: Age-related macular degeneration; Cost analysis; Intravitreal injection; Ranibizumab.

MeSH terms

  • Humans
  • Intravitreal Injections
  • Ranibizumab* / therapeutic use
  • Wet Macular Degeneration* / diagnosis
  • Wet Macular Degeneration* / drug therapy

Substances

  • Ranibizumab